NEW YORK, Oct. 12, 2011 /PRNewswire/ -- StriVectin®, the clinical anti-aging expert, was one of three honorees to receive The Skin Cancer Foundation's 2011 Skin Sense Award Tuesday night at The Plaza. The award, presented at the Foundation's annual gala, honors exceptional achievement in skin health. The company was recognized for its exclusive NIA-114™ molecule, a multi-patented, proprietary technology rooted in 30 years of research into DNA repair and skin cancer prevention. Bringing a new level of medical research and rigor to skin care, StriVectin's NIA-114™ technology yields exceptional anti-aging and skin repair results and is clinically proven to reverse the visible effects of skin damage over time.
"Our mission is to repair and rebuild healthy skin layers, because our belief is that healthy skin is truly the most beautiful skin," said Melisse Shaban, CEO of StriVectin, in accepting the award. "StriVectin is immensely proud to be bringing these discoveries to the world in unique and novel ways, and we are committed to supporting The Skin Cancer Foundation and the important work they do in the areas of awareness and research."
About StriVectin's Technology:
The development of StriVectin's exclusive Niacin (Vitamin B3) molecule called NIA-114™ is the result of over 30 years of research by Drs. Myron and Elaine Jacobson, noted biochemists, and members of the Arizona Cancer Center. It all started with their studies on the mechanisms by which cells naturally avoid the development of skin cancer that led to their findings that niacin has many functions in skin cells. Over many years, including research partially funded by the National Institutes of Health, they continued to study how niacin is involved in how cells respond to DNA damage.
With more than 14 clinical studies involving 600 subjects and 57 global patents, its unique and unrivaled mechanisms of benefi
Copyright©2010 PR Newswire.
All rights reserved